The medication is generally used to manage symptoms and provide supportive care across several key women's health domains, primarily when they are related to a hormonal imbalance. This medication is commonly used along with estrogen therapy to help with symptoms of menopause and may be used to help with the symptomatic manifestation of amenorrhea (absence of a period).

It is relevant for easing symptoms associated with Menopausal Hormone Therapy (HRT) support, fertility treatment, and the management of irregular menstrual cycles. It is applied across domains where additional symptomatic support is needed. This supportive therapeutic benefit helps to ease the overall symptom load and contributes to improved comfort during periods of heightened symptoms.

---

Supportive Information: Symptom Relief

The medication may assist with maintaining functional stability in situations involving symptoms related to systemic imbalance. This is relevant when supportive symptom management is appropriate.

Regulatory References

1. NIH MedlinePlus overview of Progesterone

Utrogest is officially licensed for use in specific adult women populations, including those receiving Hormone Replacement Therapy (HRT) adjuncts and women undergoing Assisted Reproductive Technology (ART) for luteal phase support. The medicine is not established for use in the pediatric or geriatric populations (women 65 years). Use during pregnancy is restricted to the first trimester for specific approved indications, and it is not recommended during breastfeeding.

---

Populations Who Must Not Use Utrogest

Based on regulatory documentation, Utrogest is contraindicated (absolutely prohibited) in patients with the following conditions:

• Active or history of arterial or venous thromboembolic disease (e.g., blood clots).
• Severe hepatic dysfunction (severe liver disease).
• Known, past, or suspected breast cancer or other hormone-dependent malignancies.
• Undiagnosed abnormal genital bleeding.
• Known allergy to the active substance or excipients, including soya lecithin.

Patients with conditions like renal dysfunction or a history of severe depression are eligible but require careful observation during therapy.

Interactions with other medicines and products

The interaction profile for Utrogest (Micronized Progesterone) is primarily defined by its metabolism and the effects it has on co-administered substances, as documented in official regulatory labeling.

---

Pharmacokinetic Interactions

Interactions that modify the systemic exposure of Progesterone:

• Potent Enzyme Inducers: Substances like rifampicin, phenytoin, and carbamazepine are documented to accelerate Progesterone metabolism in the liver, leading to a decreased exposure and potentially modified effect.
• Enzyme Inhibitors: Co-administration with enzyme inhibitors, such as ketoconazole, may increase the bioavailability of Progesterone.
• Antibiotics: Certain antibiotics, including ampicillins and tetracyclines, may affect the enterohepatic circulation of the hormone, potentially altering its effect.

---

Pharmacodynamic Interactions and Restrictions

Interactions where Progesterone affects other medicines or official restrictions apply:

Co-administered Substance	Documented Interaction Outcome
Ciclosporin (Cyclosporin)	Progesterone may raise the plasma concentration of this substance.
Bromocriptine	Progesterone may interfere with the effects of Bromocriptine.
Antidiabetic Agents	Progestins are noted to potentially cause a reduction in glucose tolerance.
Food / Alcohol (Oral Capsule)	Concomitant food ingestion and alcohol abuse are documented to increase the bioavailability of the oral capsule formulation.

---

Use of Utrogest is formally contraindicated in individuals with severe hepatic dysfunction or liver disease, as this condition prevents the proper metabolism of progesterone, representing a serious population-specific restriction.

Utrogest contains micronized progesterone, a steroid hormone that is structurally identical to the endogenous compound. The molecule diffuses across cell membranes and binds to intracellular progesterone receptors (PR-A and PR-B), acting as an agonist. This binding induces a conformational change in the receptor protein, leading to its dimerization and nuclear translocation.

Inside the nucleus, the activated receptor complex binds to specific DNA sequences known as Progesterone Response Elements (PREs), thereby modulating the transcription rate of target genes. In the endometrium, this cascade activates genes responsible for inducing secretory differentiation in the uterine lining. The presence of progesterone also functions as an anti-mitotic factor by decreasing the expression of estrogen receptors, thereby counteracting estrogen-driven proliferation and supporting the integrity and structural changes of the tissue.

Utrogest administration adheres to strict regulatory guidelines regarding route, frequency, and timing, which vary based on the treatment protocol. The soft capsule formulation is approved for administration via two distinct methods: oral (swallowing whole) or vaginal (local insertion).

Official Administration Guidelines

Usage Parameter	Official Instruction (Label-Based)
Route of Administration	Approved for both Oral and Vaginal use.
Dosing Schedule (HRT)	Typically 200 mg daily taken cyclically for 12 to 14 days of a menstrual cycle, or 100 mg daily taken continuously.
Dosing Schedule (ART)	Higher daily doses, such as 600 mg per day, are common for luteal phase support, often administered vaginally in divided doses.
Timing and Food Relationship	Oral administration must be taken as a single dose at bedtime and specifically without food (e.g., at least two hours after a meal).
Missed Dose Rule	If a dose is missed, continue the regimen at the next scheduled time; the dose must not be doubled to compensate.
Population Use	No specific dose adjustments are required for older adults; the product has no relevant use in the paediatric population.

These instructions define how the medicine must be taken to align with official regulatory standards, establishing patterns for sustained or cyclic use. The procedural structure determines the correct administration route and exact timing conditions, such as the requirement for the oral dose to be taken at bedtime and apart from food, without providing clinical advice or therapeutic explanations.

Research Evidence / Overview of Studies for Utrogest

Evidence for Use in Menopausal Hormone Therapy (HRT) Support

Research examined the use of micronized progesterone in women who are postmenopausal and still have a uterus, which requires hormonal support alongside estrogen therapy. Studies used a mix of large, long-term observational cohort studies and shorter Randomized Controlled Trials (RCTs). Researchers specifically examined endometrial health and systemic outcomes.

Studies reported measurements of endometrial health endpoints following cycles of administration. Observational cohorts reported data show patterns related to systemic outcomes, but research comparing this to various progestogens is limited. Findings also included data on the occurrence of uterine bleeding.

However, long-term comparative systemic data often stems from observational studies, introducing methodological variability and limiting certainty. Few RCTs compare all long-term profiles head-to-head, and there is limited consensus on oral versus vaginal administration for all measured systemic outcomes.

---

Evidence for Luteal Phase Support in Fertility Treatment (ART)

Micronized progesterone was evaluated in research contexts as Luteal Phase Support (LPS) in women undergoing fertility treatments like IVF and embryo transfer cycles. The evidence base is primarily composed of numerous Randomized Non-inferiority Trials and comprehensive systematic reviews.

These studies monitored reproductive endpoints, such as Ongoing Pregnancy Rate and Live Birth Rate (LBR). Trials were conducted to evaluate outcomes against an established treatment, and studies reported patterns in the maintenance of pregnancy. Neonatal outcomes were also described by researchers.

Variability in the specific dose and the way the treatment was given (e.g., vaginal gel, capsule, oral) across trials means that findings were mixed, limiting the ability to draw a single, unified conclusion about the optimal approach. Limited data are available in older women (e.g., over 40) undergoing ART cycles.

---

Evidence for the Prevention of Spontaneous Preterm Birth

Research has explored the use of micronized progesterone in pregnant women who face a higher risk of delivering too early due to factors like a prior history of spontaneous preterm birth or a short cervix. This use was evaluated in Randomized Placebo-Controlled Trials (RCTs).

Studies focused on measuring the gestational age at delivery, specifically tracking the rate of spontaneous delivery before 37 weeks. Trials described the measurement of the time until delivery when administration was initiated in the mid-trimester. Studies reported how gestational age at birth evolved in the observed populations. Research regarding use in multifetal (twin) pregnancies was limited and findings were inconsistent.

Key Studies & References

1. NIH MedlinePlus Overview of Progesterone (Oral)

Common questions about Utrogest (FAQ)

Q: What is the difference between Utrogest and other progesterone treatments?

According to official documents, Utrogest contains micronized progesterone, which is a form of the hormone that is structurally bioidentical (an exact match) to the progesterone naturally produced in the human body. This formulation is the key difference that sets it apart from synthetic progestins used in some other treatments.

Q: Does Utrogest contain any estrogen?

No, the active ingredient in Utrogest is solely micronized progesterone. The medicine is often prescribed to be used alongside separate estrogen treatments as part of a combined hormone replacement therapy (HRT) regimen, but it does not contain estrogen itself.

Q: Why is Utrogest sometimes prescribed as a vaginal capsule instead of an oral tablet?

The regulatory information indicates that the vaginal route is often chosen to achieve adequate therapeutic levels in the uterine lining while limiting the overall amount of the medicine in the bloodstream. This lower systemic exposure is associated with fewer systemic side effects, such as drowsiness or dizziness.

Q: Is Utrogest available over the counter in some countries?

Official regulatory categorization across approved markets defines Utrogest as a prescription-only medicine. Therefore, it is generally not available over-the-counter and requires a valid medical prescription.

Q: Is Utrogest the same thing as a birth control pill?

No. Official prescribing documents explicitly state that Utrogest is not a contraceptive and does not protect against pregnancy. Its function is to provide hormonal support for specific approved medical conditions.

Q: How long does it typically take for a person to notice the expected effects of Utrogest?

Official documents state that while the protective effect on the uterine lining begins quickly, it may take a period of a few weeks, or up to three months, for the body to adjust. This adjustment time is relevant, especially when the medicine is used for relieving menopausal symptoms.

Q: Do the therapeutic effects of Utrogest build up over several weeks?

Regulatory patient information suggests that the full, steady-state benefits and effects are often established after an initial adjustment period. Furthermore, side effects commonly reported at the start of treatment often become less pronounced as the body becomes accustomed to the medication over several weeks.

Q: Is Utrogest prescribed for short-term use or long-term maintenance in general clinical practice?

Official schedules for Utrogest indicate it is used for both. For fertility treatments (Luteal Phase Support), it is prescribed for short-term use. In Hormone Replacement Therapy (HRT), it can be used for long-term continuous or cyclic maintenance depending on the specific regimen.

Q: How long does Utrogest stay detectable in the system after treatment is stopped?

Regulatory-cited pharmacokinetic studies report the elimination half-life (the time it takes for half the medicine to leave the bloodstream) of progesterone is typically around 20 to 22 hours after oral administration. Based on this, the active ingredient is eliminated from the body within a few days of stopping treatment.

Q: Are the reported side effects of Utrogest different when taken orally versus vaginally?

Yes. Official safety information indicates that systemic effects like drowsiness, somnolence, and dizziness are primarily observed with the oral route due to the way the body processes the dose. These particular effects are not typically reported when the medicine is used vaginally.

Q: What are some of the documented, non-specific changes in mood associated with Utrogest use?

Official safety documentation notes that mood changes, including low mood or depression, are a possible adverse effect of progestogen use. The regulatory label describes that persistent changes in mood may require discussion with a prescribing healthcare provider.

Q: Are there any known long-term side effects associated with continuous Utrogest use?

Regulatory warnings highlight that the main long-term risks associated with progestogen use, particularly in combination with estrogen for HRT, involve thromboembolic events (blood clots) and the necessity of monitoring for hormone-dependent malignancies (such as breast cancer).

Q: What is the general information regarding taking Utrogest with herbal supplements or multivitamins?

Official prescribing information warns that certain substances, specifically the herbal remedy St. John's wort, may interfere with and reduce the effectiveness of Utrogest. Due to the lack of formal testing for many products, regulatory labels generally note the potential for drug interactions with herbal remedies and suggest professional consultation.

Q: Is Utrogest ever used in men or children for off-label purposes?

Utrogest is officially licensed solely for use in adult women for specific hormonal indications. Regulatory documentation explicitly states that the product has no relevant use in the paediatric population and is not indicated for men.

Q: Is Utrogest considered a treatment option for pre-menopausal women?

Yes. According to official guidelines, Utrogest is used in perimenopausal women (those still having periods) as part of a sequential or cyclical Hormone Replacement Therapy (HRT) regimen. Its purpose in this context is to protect the uterine lining during the estrogen-only phases of treatment.

Q: Are there large-scale international studies that document the overall safety profile of Utrogest?

Official regulatory evidence confirms that the safety profile is established using data from large, long-term observational cohort studies, such as those related to combined HRT, as well as randomized trials. These studies focus on specific endpoints like endometrial health and live birth rates.

Q: Does Utrogest cause weight changes, and if so, how is this typically described in official documentation?

Regulatory documentation sometimes lists oedema, which is fluid retention or swelling, as a potential side effect. This condition can potentially result in minor, non-fat-related weight changes. Weight gain not specifically due to oedema is not typically listed as a common side effect.

Q: What are the general rules regarding driving or operating machinery while on Utrogest?

The oral route is associated with systemic effects like drowsiness and dizziness. Official regulatory safety documents advise that if these symptoms occur, operating machinery or driving should be avoided. The advice is included in the instructions to take the oral capsule at bedtime to minimize the effect during daylight hours.

Q: Is it necessary to use Utrogest at exactly the same time every day?

Official instructions for oral use emphasize taking the dose at bedtime to help manage potential drowsiness. While this implies consistency in the time of day for routine, the official guidance for a missed dose focuses on continuing the regimen at the next scheduled time, rather than stressing a specific hourly precision.

The storage and disposal of Utrogestan capsules are strictly defined by regulatory requirements to ensure product quality and safety.

Official Storage Conditions

Requirement	Official Regulatory Statement
Temperature	Store at room temperature below 30 C; Do not refrigerate (per some regional labels).
Protection	Keep the medicine in its original package and blister pack to protect it from light and moisture.
Child Safety	Keep this medicine out of the sight and reach of children.
Stability	The product must not be used after the expiry date shown on the packaging (typically 3 years).

Disposal Requirements

Unused or expired Utrogestan must be disposed of according to local requirements. It is explicitly stated in patient leaflets not to throw medicines away via household waste or wastewater.

To dispose of the product, consult a pharmacist or utilize a local drug take-back program, as these measures help protect the environment and prevent accidental exposure.